PERCEPT study

Prospective observational study of patient characteristics, efficacy, and safety of patients prescribed dupilumab in Japanese patients with COPD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1020250021

Enrollment

120

Registered

2025-10-06

Start date

2025-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease(COPD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are willing and able to sign informed consent for the use of anonymized clinical data in this non-interventional study. 2. 20 years or older 3. Patients who have started dupilumab treatment for COPD in clinical practice by the attending physician. (Use of dupilumab for other conditions or concurrent use of other biologic agents is at the discretion of the treating physician.)

Exclusion criteria

Exclusion criteria: 1. Participation in an ongoing interventional or clinical trial that may affect the assessment of this study, as judged by the treating physician. 2. Patients with acute or chronic diseases that, in the judgment of the treating physician, may affect the completion of questionnaires, participation in this study, or interpretation of the results.

Design outcomes

Primary

Measure	Time frame
Descriptive statistical analysis of demographic characteristics (age, sex, BMI, smoking history) and clinical characteristics (COPD severity, complications, IgE [total and specific], blood eosinophil count, FeNO, respiratory function test findings, COPD Assessment Test [CAT] score, modified Medical Research Council Dyspnea Scale [mMRC], number of exacerbations [one year prior to baseline]).	—

Secondary

Measure	Time frame
Annualized rate of moderate and severe COPD exacerbations 12 months since initiation of dupilumab compared to the annual exacerbation rate of the previous year Time to the first moderate or severe exacerbations over time. Change over time in pre- and post-bronchodilator FEV1 from study start to month 12. Change over time in pre- and post FEV1/FVC from study start to month 12. Change over time in CAT Score from study start to month 12. Change over time in mMRC Score from study start to month 12. Number of hospitalizations after 12 months of dupilumab treatment vs. the year before study start. Changes in biomarkers (peripheral blood EOS, IgE [total and specific], and FeNO) measured after the initiation of dupilumab.	—

Measure

Time frame

Annualized rate of moderate and severe COPD exacerbations 12 months since initiation of dupilumab compared to the annual exacerbation rate of the previous year Time to the first moderate or severe exacerbations over time. Change over time in pre- and post-bronchodilator FEV1 from study start to month 12. Change over time in pre- and post FEV1/FVC from study start to month 12. Change over time in CAT Score from study start to month 12. Change over time in mMRC Score from study start to month 12. Number of hospitalizations after 12 months of dupilumab treatment vs. the year before study start. Changes in biomarkers (peripheral blood EOS, IgE [total and specific], and FeNO) measured after the initiation of dupilumab.

—

Contacts

Public ContactNaoya Fujino

Tohoku University Hospital

naoya.fujino.d2@tohoku.ac.jp+81-22-717-8539

Outcome results